Connect with us

Published

on

SpaceX and California-based space company Vast have announced a call for research proposals for experiments to be conducted aboard the upcoming Haven-1 space station and the SpaceX Dragon spacecraft. The Haven-1 module is scheduled for launch in August on a SpaceX Falcon 9 rocket, with a subsequent Crew Dragon mission transporting astronauts to the orbiting outpost. The initiative aims to facilitate scientific studies that advance human space exploration and habitation. Proposals will be accepted until 15 March, with selected projects gaining access to the orbital laboratory and crew assistance at no cost, though direct financial support for research will not be provided.

Focus on Human Physiology and Autonomous Research

According to the statement released by Vast, submissions should centre on biological and physiological experiments analysing microgravity’s effects on the human body, alongside autonomously executable or crew-assisted payloads suitable for low-Earth orbit missions. The research is expected to build on findings from the International Space Station (ISS), which is nearing retirement by the end of the decade. As reported, Vast Chief Executive Officer Max Haot said that collaboration with the scientific community would enable ground-breaking research to address critical challenges in human spaceflight while also offering potential benefits for life on Earth.

Vast’s Plans for Future Expansion

The Haven-1 module has been designed to support future expansion, with plans for additional modules such as Haven-2. During the 75th International Astronautical Congress in Milan, Haot revealed that Vast aims for Haven-2 to qualify for NASA’s Commercial LEO Destination (CLD) contract in 2026. Several companies, including Axiom Space, Northrop Grumman, Nanoracks, and Sierra Space, are also developing private space stations to ensure continued orbital presence after the ISS is decommissioned.

For the latest tech news and reviews, follow Gadgets 360 on X, Facebook, WhatsApp, Threads and Google News. For the latest videos on gadgets and tech, subscribe to our YouTube channel. If you want to know everything about top influencers, follow our in-house Who’sThat360 on Instagram and YouTube.


iQOO Neo 10R to Launch in India in an Exclusive Dual-Tone Colourway



AI Study Finds Organic Molecules on Ceres Likely Came from Asteroid Impacts

Related Stories

Continue Reading

Science

Scientists Control Kelvin Waves in Superfluid Helium for First Time

Published

on

By

Scientists Control Kelvin Waves in Superfluid Helium for First Time

For the first time, researchers have successfully controlled and observed Kelvin waves in superfluid helium-4, marking a significant step in understanding energy dissipation in quantum systems. The study has provided a controlled method to excite these helical waves, which had previously only been observed in unpredictable conditions. The research opens new possibilities for studying quantised vortices and their role in energy transfer at the quantum level.

Controlled Excitation of Kelvin Waves

According to the study published in Nature Physics, also available on arXiv, Kelvin waves—first described by Lord Kelvin in 1880—are helical disturbances that travel along vortex lines in superfluid systems. These waves play a crucial role in energy dissipation within quantum fluids but have remained difficult to study due to the challenges of controlled excitation.

Associate Professor Yosuke Minowa from Kyoto University, the lead author of the study, told Phys.org that the breakthrough occurred unexpectedly. An electric field was applied to a nanoparticle decorating a quantised vortex with the intention of moving the structure. Instead, the vortex core exhibited a distinct wavy motion, leading researchers to shift their focus toward controlled Kelvin wave excitation.

Superfluid Properties and Quantum Vortex Behaviour

Superfluid helium-4, which exhibits quantum effects at macroscopic scales when cooled below 2.17 Kelvin, has no viscosity, allowing it to flow without friction. This unique state prevents energy from dissipating as heat, leading to the formation of Kelvin waves when disturbances occur in the vortex lines of the fluid. The research team demonstrated that these waves, rather than traditional fluid turbulence, provide an essential mechanism for energy transfer in superfluid systems.

Nanoparticles Used for Wave Visualisation

To track the motion of Kelvin waves, the researchers introduced silicon nanoparticles into superfluid helium-4 at 1.4 Kelvin by directing a laser at a silicon wafer submerged in the fluid. Some nanoparticles became trapped within vortex cores, making them visible under controlled conditions. A time-varying electric field was then applied, forcing oscillations in the trapped particles and generating a helical wave along the vortex.

Experiments were conducted across different excitation frequencies ranging from 0.8 to 3.0 Hertz. A dual-camera system allowed for three-dimensional reconstruction of the wave’s motion, confirming its helical nature.

Experimental Confirmation and Future Research

Prof. Minowa explained to Phys.org that proving the observed phenomenon was indeed a Kelvin wave required an in-depth analysis of dispersion relations, phase velocity, and three-dimensional dynamics. By reconstructing the vortex’s motion in 3D, the researchers provided direct evidence of the wave’s handedness, confirming its left-handed helical structure—something never experimentally demonstrated before.

To validate their findings, the team developed a vortex filament model, which simulated Kelvin wave excitation under similar conditions. These simulations confirmed that forced oscillations of a charged nanoparticle generated helical waves in both directions, aligning with experimental results.

The study introduces a new approach for studying Kelvin waves in superfluid helium, offering insights into the mechanics of quantised vortices. Future research may explore the nonlinearity and decay processes of Kelvin waves, potentially revealing further details about quantum fluid dynamics.

Continue Reading

Science

A New Method Improves Kesterite Solar Cells, Making Them More Efficient

Published

on

By

A New Method Improves Kesterite Solar Cells, Making Them More Efficient

Efforts to improve the efficiency of kesterite-based solar cells have shown progress, with researchers achieving a record power conversion efficiency (PCE) of 11.4 percent. A new approach using hydrogen annealing has been applied to enhance carrier collection in Cu₂ZnSnS₄ (CZTS) solar cells. This technique involves heating the material in a hydrogen-rich environment, which redistributes key elements and reduces energy losses. The findings indicate that hydrogen annealing could be a scalable method to enhance performance, making CZTS a viable option for tandem solar cells.

Hydrogen Annealing Improves Carrier Collection

According to a study published in Nature Energy, researchers at the University of New South Wales explored the impact of hydrogen annealing on CZTS solar cells. The process was found to redistribute sodium and oxygen within the material, reducing defects and enhancing carrier transport. Carrier recombination, a key challenge in CZTS cells, was mitigated, leading to improved efficiency.

Kaiwen Sun, senior author of the study, told Tech Xplore that the aim was to develop a sustainable and cost-effective alternative for next-generation photovoltaics. He explained that hydrogen plays a crucial role in passivating defects near the absorber surface, leading to improved carrier collection.

Potential for Wider Applications

Beyond CZTS, hydrogen annealing has demonstrated promise in enhancing other thin-film solar cell materials, such as copper indium gallium selenide (CIGS). Researchers believe this technique could be applied to various photovoltaic technologies to improve efficiency while maintaining environmental benefits.

Future work will focus on increasing the efficiency of CZTS solar cells beyond 15 percent while preserving their affordability and sustainability. Refinements in the annealing process and further material optimisations are expected to contribute to more efficient solar energy solutions.

For the latest tech news and reviews, follow Gadgets 360 on X, Facebook, WhatsApp, Threads and Google News. For the latest videos on gadgets and tech, subscribe to our YouTube channel. If you want to know everything about top influencers, follow our in-house Who’sThat360 on Instagram and YouTube.


FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades



Budget 2025: Tech in Focus With Framework for GCCs, New ‘Fund of Funds’ for startups, CoE for AI

Continue Reading

Science

FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades

Published

on

By

FDA Approves Suzetrigine, First Non-Opioid Painkiller in Decades

The United States Food and Drug Administration (FDA) has approved suzetrigine, a non-opioid painkiller, for short-term pain management. This approval marks the first time in over two decades that a new pain relief mechanism has been introduced. Suzetrigine, which selectively targets sodium channels on pain-sensing neurons, has been developed as an alternative to opioids, which have been linked to addiction and overdose crises. The drug is expected to provide pain relief similar to opioids but without the associated risks of dependency, sedation, or overdose.

Targeting Sodium Channels for Pain Relief

According to research presented at a major anesthesiology conference last year, suzetrigine, now branded as Journavx, works by blocking the NaV1.8 sodium channel subtype, which plays a key role in transmitting pain signals. Unlike traditional sodium channel-blocking drugs like lidocaine, which act on all nine subtypes indiscriminately, suzetrigine is designed to target pain-sensing neurons specifically. This selectivity reduces side effects and allows the drug to be taken orally rather than requiring local application.

Clinical Trials and Effectiveness

In clinical trials, more than 80% of participants reported effective pain relief after surgery or injury. Trials on individuals undergoing procedures such as bunion removal and tummy tucks showed that suzetrigine provided pain relief comparable to opioid-based regimens, with fewer side effects. Paul White, an anesthesiologist at Cedars-Sinai Medical Center, stated to Nature, that increasing non-opioid options could significantly reduce opioid dependency.

Challenges and Future Prospects

Suzetrigine has been priced at $15.50 per pill, a cost that remains higher than generic opioids but is considered cost-effective given the expenses associated with opioid addiction treatment. While its effectiveness in chronic pain conditions remains uncertain, pharmaceutical companies are advancing similar drugs targeting sodium channels, aiming to expand non-opioid pain relief options.

Continue Reading

Trending